Personal information

No personal information available

Activities

Collapse all

Works (25)

Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper

Clinical Pharmacology & Therapeutics
2024-10 | Journal article
DOI: 10.1002/cpt.3350
Contributors: Aarti Sawant‐Basak; Shweta Urva; Jatinder Kaur Mukker; Sebastian Haertter; Dean Mariano; Dolly A. Parasrampuria; Kosalaram Goteti; Ravi Shankar Prasad Singh; Manoj Chiney; Michael Z. Liao et al.
Source: check_circle
Crossref

KRAS: Structure, function, and development of anticancer drugs

Cancer-Leading Proteases
2020 | Other
DOI: 10.1016/b978-0-12-818168-3.00013-9
Contributors: Dolly A. Parasrampuria; Alex Yu; Nahor Haddish-Berhane
Source: Self-asserted source
Dolly Parasrampuria via Crossref Metadata Search

Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective

Drug Discovery Today
2020-10 | Journal article
DOI: 10.1016/j.drudis.2020.07.014
Contributors: Dolly A. Parasrampuria; Rajesh Bandekar; Thomas A. Puchalski
Source: check_circle
Crossref

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.

The Lancet. Haematology
2020-03 | Journal article
DOI: 10.1016/s2352-3026(20)30070-3
PMID: 32213342
Contributors: Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M et al.
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.

British journal of haematology
2020-02 | Journal article
DOI: 10.1111/bjh.16446
PMID: 32068255
Contributors: Parasrampuria DA; He J; Zhang L; Muresan B; Hu P; Nemat S; Hashim M; Lam A; Appiani C; Cavo M et al.
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.

Contraception
2020-01 | Journal article
DOI: 10.1016/j.contraception.2019.12.012
PMID: 31935382
Contributors: Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.

British journal of haematology
2019-03 | Journal article
DOI: 10.1111/bjh.15847
PMID: 30847896
Contributors: Kearns P; Zwaan CM; Reinhardt D; Gibson B; Moreno L; Nysom K; Nakahara S; Huang F; Zhou W; Parasrampuria DA et al.
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Population Pharmacokinetic Analysis of Decitabine in Pediatric Patients With Acute Myeloid Leukemia.

Journal of clinical pharmacology
2018-12 | Journal article
DOI: 10.1002/jcph.1357
PMID: 30536675
Contributors: Zhou W; Parasrampuria DA; Nemat S; Nakahara S; Poggesi I; Massarella J; Zhang L; Appiani C
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.

The AAPS journal
2018-03 | Journal article
DOI: 10.1208/s12248-018-0204-y
PMID: 29536211
Contributors: Parasrampuria DA; Benet LZ; Sharma A
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.

British journal of clinical pharmacology
2016-09 | Journal article
DOI: 10.1111/bcp.13092
PMID: 27530188
PMC: PMC5099547
Contributors: Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa.

Clinical pharmacokinetics
2016-06 | Journal article
DOI: 10.1007/s40262-015-0342-7
PMID: 26620048
PMC: PMC4875962
Contributors: Parasrampuria DA; Truitt KE
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects.

Clinical drug investigation
2016-02 | Journal article
DOI: 10.1007/s40261-015-0357-8
PMID: 26597179
PMC: PMC4740573
Contributors: Parasrampuria DA; Weilert D; Maa JF; Dishy V; Kochan J; Shi M; Brown KS
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Response of authors to Ganju and Dias' comments on 'Inclusion of Placebos and Blinding for Ascending Dose First-in-Human Studies and Other Underpowered Phase 1 Studies Has Not Been Justified and on Balance is Not Useful' by D. A. Parasrampuria and L. Z. Benet.

Basic & clinical pharmacology & toxicology
2015-10 | Journal article
DOI: 10.1111/bcpt.12483
PMID: 26435387
Contributors: Parasrampuria DA; Benet LZ
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.

Thrombosis research
2015-07 | Journal article
DOI: 10.1016/j.thromres.2015.07.012
PMID: 26298619
Contributors: Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule.

Journal of clinical pharmacology
2015-06 | Journal article
DOI: 10.1002/jcph.540
PMID: 25969414
PMC: PMC4755158
Contributors: Parasrampuria DA; Kanamaru T; Connor A; Wilding I; Ogata K; Shimoto Y; Kunitada S
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

Thrombosis and haemostasis
2015-01 | Journal article
DOI: 10.1160/th14-06-0547
PMID: 25566930
Contributors: Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful.

Basic & clinical pharmacology & toxicology
2014-12 | Journal article
DOI: 10.1111/bcpt.12352
PMID: 25406995
Contributors: Parasrampuria DA; Benet LZ
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.

Journal of clinical pharmacology
2007-10 | Journal article
DOI: 10.1177/0091270007308615
PMID: 17962423
Contributors: Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.

Journal of clinical psychopharmacology
2007-10 | Journal article
DOI: 10.1097/jcp.0b013e3181515205
PMID: 17873677
Contributors: Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

The American journal of psychiatry
2006-03 | Journal article
DOI: 10.1176/appi.ajp.163.3.387
PMID: 16513858
Contributors: Spencer TJ; Biederman J; Ciccone PE; Madras BK; Dougherty DD; Bonab AA; Livni E; Parasrampuria DA; Fischman AJ
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p38 mitogen-activated protein kinase inhibitor: a first-in-human study.

Journal of clinical pharmacology
2003-04 | Journal article
DOI: 10.1177/0091270002250615
PMID: 12723461
Contributors: Parasrampuria DA; de Boer P; Desai-Krieger D; Chow AT; Jones CR
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation.

Journal of clinical pharmacology
2002-03 | Journal article
DOI: 10.1177/00912700222011337
PMID: 11865967
Contributors: Parasrampuria DA; Lantz MV; Birnbaum JL; Vincenti FG; Benet LZ
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.

Pharmaceutical research
2001-01 | Journal article
DOI: 10.1023/a:1011070509191
PMID: 11336351
Contributors: Parasrampuria DA; Lantz MV; Benet LZ
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Biliary elimination of bromsulphthalein, phenolphthalein, and doxorubicin released from microspheres following intravenous administration.

Biopharmaceutics & drug disposition
1993-03 | Journal article
DOI: 10.1002/bdd.2510140209
PMID: 8453027
Contributors: Hickey AJ; Tian Y; Parasrampuria D; Kanke M
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central

Percutaneous delivery of proteins and peptides using iontophoretic techniques.

Journal of clinical pharmacy and therapeutics
1991-02 | Journal article
DOI: 10.1111/j.1365-2710.1991.tb00278.x
PMID: 2026670
Contributors: Parasrampuria D; Parasrampuria J
Source: Self-asserted source
Dolly Parasrampuria via Europe PubMed Central
How many people are using ORCID?